Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

62.40
-0.4600-0.73%
Post-market: 63.000.6000+0.96%18:11 EDT
Volume:15.87M
Turnover:998.88M
Market Cap:127.03B
PE:13.74
High:64.13
Open:63.28
Low:62.40
Close:62.86
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.11
T/O Rate:0.78%
Dividend:2.51
Dividend Rate:4.02%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.69
PE(LYR):18.03

Loading ...

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos® (Mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm) in Adults and Pediatric Patients*

THOMSON REUTERS
·
44 mins ago

Bristol-Myers Squibb's Camzyos to Treat Heart Condition Receives FDA Approval for Pediatric Patients

MT Newswires Live
·
2 hours ago

FDA: Approved Camzyos (Mavacamten) Capsules as First Treatment for Children with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Website

THOMSON REUTERS
·
3 hours ago

FDA Approves First Drug to Improve Functional Capacity and Symptoms in Children with Rare Inherited Heart Condition

THOMSON REUTERS
·
3 hours ago

FDA: Camzyos Carries Boxed Warning for Heart Failure Risk, Restricted to Rems Program

THOMSON REUTERS
·
3 hours ago

FDA approves Bristol Myers’ Camzyos capsules for children with oHCM

TIPRANKS
·
3 hours ago

Bristol-Myers' Protocol Changes Add Risk, Keep Admilparant on Track, UBS Says

MT Newswires Live
·
5 hours ago

BMY Expands Real-World Cancer Data With New AUGTYRO Study in Korea

TIPRANKS
·
5 hours ago

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

Helix BioPharma Names Karen Krumeich Board Chair, Adds Three Directors

Reuters
·
Sep 29

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 29

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

Bristol-Myers Squibb Says Zenbexus Combination Doubles MRD-Negative Complete Response in Multiple Myeloma Trial

MT Newswires Live
·
Sep 25

Bristol Myers reports results from prespecified analysis of EXCALIBER-RRMM trial

TIPRANKS
·
Sep 25

Bristol Myers Squibb Wins FDA Accelerated Approval for Zenbexus Combo in Multiple Myeloma

Reuters
·
Sep 25

Bristol Myers Squibb Announces First Presentation of Results for Zenbexus™ (Iberdomide) in Combination with Daratumumab from Phase 3 Excaliber-Rrmm Trial in Relapsed or Refractory Multiple Myeloma

THOMSON REUTERS
·
Sep 25

BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline

TIPRANKS
·
Sep 25

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

RBC Capital Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

TIPRANKS
·
Sep 24